Advertisement

Advertisement
Aditya Bardia, MD, MPH, on Triple-Negative Breast Cancer: Sacituzumab Govitecan vs Treatment of Physician’s Choice

Aditya Bardia, MD, MPH, on Triple-Negative Breast Cancer: Sacituzumab Govitecan vs Treatment of Physician’s Choice

IMpassion131: No Benefit for Atezolizumab Plus Paclitaxel in Triple-Negative Breast Cancer

Based on some unexpected negative results, oncologists using atezolizumab for metastatic triple-negative breast cancer should pair it with nab-paclitaxel, not paclitaxel. In contrast to the overall survival benefit shown for atezolizumab plus nab-paclitaxel in the previous IMpassion130 trial—further validated in an update—atezolizumab plus paclitaxel failed to improve outcomes in IMpassion131, which was reported at the ESMO Virtual Congress 2020.

Adjuvant Trastuzumab With or Without Chemotherapy for Older Patients With HER2-Positive Early Breast Cancer

In the Japanese RESPECT trial reported in the Journal of Clinical Oncology, Sawaki et al found that noninferiority of adjuvant trastuzumab alone vs with chemotherapy was not shown for disease-free survival among women with HER2-positive breast cancer between the ages of 70 and 80 years. However, a small difference in restricted mean survival time was observed, and health-related quality of life was better with trastuzumab monotherapy.

Addition of Atezolizumab to Neoadjuvant Chemotherapy in Early-Stage Triple-Negative Breast Cancer: IMpassion031 Trial

Addition of Atezolizumab to Neoadjuvant Chemotherapy in Early-Stage Triple-Negative Breast Cancer: IMpassion031 Trial

As reported in The Lancet by Elizabeth A. Mittendorf, MD, and colleagues, results from the phase III IMpassion031 trial showed improved pathologic complete response rates with the addition of atezolizumab to sequential nab-paclitaxel and anthracycline-based neoadjuvant chemotherapy in patients with early-stage triple-negative breast cancer.

Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With Early Breast Cancer at High Risk of Recurrence: monarchE Trial

Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With Early Breast Cancer at High Risk of Recurrence: monarchE Trial

As reported in the Journal of Clinical Oncology by Stephen R.D. Johnston, MD, PhD, and colleagues, the phase III monarchE trial has shown that adjuvant abemaciclib plus endocrine therapy significantly improved invasive disease–free survival vs endocrine therapy alone in patients with hormone receptor–positive, HER2-negative, node-positive early breast cancer who are at high risk for disease recurrence.

Breast Induration With Hypofractionated vs Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma in Situ

In a Danish Breast Cancer Group phase III trial (DBCG HYPO) reported in the Journal of Clinical Oncology, Offersen et al found no difference in the rates of breast induration with moderately hypofractionated vs standard fractionated radiotherapy in women with early breast cancer or ductal carcinoma in situ.

Advertisement


Advertisement